

The **TRANSPLANT PATIENT**

Biological, psychiatric, and ethical
issues in organ transplantation

Edited by

Paula T. Trzepacz

Eli Lilly and Company, Indianapolis, and
University of Mississippi Medical Center

and

Andrea F. DiMartini

Psychiatric Consultation – Liaison Program,
University of Pittsburgh Medical Center,
Western Psychiatric Institute and Clinic



CAMBRIDGE
UNIVERSITY PRESS

PUBLISHED BY THE PRESS SYNDICATE OF THE UNIVERSITY OF CAMBRIDGE
The Pitt Building, Trumpington Street, Cambridge, United Kingdom

CAMBRIDGE UNIVERSITY PRESS
The Edinburgh Building, Cambridge CB2 2RU, UK <http://www.cup.cam.ac.uk>
40 West 20th Street, New York, NY 10011-4211, USA <http://www.cup.org>
19 Stamford Road, Oakleigh, Melbourne 3166, Australia
Ruiz de Alarcón 13, 28014 Madrid, Spain

© Cambridge University Press 2000

This book is in copyright. Subject to statutory exception
and to the provisions of relevant collective licensing agreements,
no reproduction of any part may take place without
the written permission of Cambridge University Press.

First published 2000

Printed in the United Kingdom at the University Press, Cambridge

Typeset in Minion 10/12 pt [vN]

A catalogue record for this book is available from the British Library

Library of Congress Cataloguing in Publications data

The transplant patient: biological, psychiatric, and ethical issues in organ transplantation /
edited by Paula T. Trzepacz and Andrea F. DiMartini.

p. cm.

Includes index.

ISBN 0 521 55354 7 (hb)

1. Transplantation of organs, tissues, etc. – Physiological aspects. 2. Transplantation of
organs, tissues, etc. – Psychological aspects. 3. Transplantation of organs, tissues, etc. –
Moral and ethical aspects. I. Trzepacz, Paula T. II. DiMartini, Andrea F.

[DNLM: 1. Organ Transplantation – psychology. 2. Ethics, Medical. 3. Organ
Transplantation – physiology. WO 690 T772 2000]

RD120.7.T657 2000

617.9'5 – dc21

DNLM/DLC

for Library of Congress 99-25872 CIP

ISBN 0 521 553547 hardback

Every effort has been made in preparing this book to provide accurate and up-to-date
information which is in accord with accepted standards and practice at the time of publication.
Nevertheless, the authors, editors and publisher can make no warranties that the information
contained herein is totally free from error, not least because clinical standards are constantly
changing through research and regulation. The authors, editors and publisher therefore
disclaim all liability for direct or consequential damages resulting from the use of material
contained in this book. Readers are strongly advised to pay careful attention to information
provided by the manufacturer of any drugs or equipment that they plan to use.

Contents

	<i>List of contributors</i>	vii
	<i>Preface</i>	ix
1	The mystique of transplantation: biologic and psychiatric considerations Thomas E. Starzl	1
2	Psychosocial screening and selection of candidates for organ transplantation James L. Levenson and Mary Ellen Olbrisch	21
3	Psychosocial issues in living organ donation Galen E. Switzer, Mary Amanda Dew, and Robert K. Twillman	42
4	Quality of life in organ transplantation: effects on adult recipients and their families Mary Amanda Dew, Jean M. Goycoolea, Galen E. Switzer, and Aishe S. Allen	67
5	Quality of life of geriatric patients following transplantation: short- and long-term outcomes Maria Paz González, Abraham Sudilovsky, Julio Bobes, and Andrea F. DiMartini	146
6	Cognitive assessment in organ transplantation Ralph E. Tarter and JoAnn Switala	164
7	Pharmacologic issues in organ transplantation: psychopharmacology and neuropsychiatric medication side effects Paula T. Trzepacz, Babu Gupta, and Andrea F. DiMartini	187
8	Alcoholism and organ transplantation Andrea F. DiMartini and Paula T. Trzepacz	214
9	Ethics and images in organ transplantation Grant Gillett	239

10	Psychoneuroimmunology and organ transplantation: theory and practice Richard Kradin and Owen Surman	255
11	Pediatric transplantation Robert D. Canning and Margaret L. Stuber	275
12	Current trends and new developments in transplantation Maureen Martin	287
	<i>Index</i>	305

The mystique of transplantation: biologic and psychiatric considerations

Thomas E. Starzl M.D., Ph.D.

Most major advances in medicine spring from discoveries in basic science and are therefore predictable, or at least logical. Organ transplantation was the supreme exception to the rule. Although the potential benefit of whole-organ replacement in the absence of an immune barrier was dramatically demonstrated with the identical-twin kidney transplantation performed, in December 1954, by Joseph E. Murray (Nobel Laureate, 1990; Merrill et al. 1956), this achievement only confirmed what already was known to be possible with identical-twin skin grafts (Padgett 1932; Brown 1937). In 1961, two months after receiving the 1960 Nobel Prize for research in immunology, Macfarland Burnet wrote in the *New England Journal of Medicine* that “much thought has been given to ways by which tissues or organs not genetically and antigenetically identical with the patient might be made to survive and function in the alien environment. On the whole, the present outlook is highly unfavorable to success...” (Burnet 1961).

This grim prospect, only a third of a century ago, faced the pioneer organ recipients whose courage in offering themselves up for human experimentation made it possible to crack the immunologic barrier (Starzl 1992). For three decades after this was done, there was no explanation for what had been accomplished. The resulting mystique of transplantation as well as the unpredictable outcome of these procedures created a fertile emotional soil for psychiatric complications. Consequently, when the light of understanding was finally switched on in 1992, it was as much a spiritual as a scientific awakening. The acquisition of this insight exposed a seminal principle of allograft acceptance that is the same with all kinds of whole organs.

The immunologic barrier: the one-way paradigm

What was the immunologic barrier described in such pessimistic terms by Burnet, who saw no way that a transplanted histoincompatible organ could pass through the seemingly inviolate barrier of immunologic reactivity? In the identical-twin kidney transplantations, the problem was by-passed, but in all other cases, it was necessary to reckon with two potential complications,

either separately or together: rejection and graft-versus-host disease (GVHD).

Rejection

Although the details remain incomplete today, there was little mystery about the general meaning of rejection, following its elucidation in 1944 by Medawar (Nobel co-Laureate with Burnet 1960) as an immunologic event (Medawar 1944). This great contribution created the indelible image that transplantation involved a one-way immune reaction. Thus, a tissue (or organ) allograft was a defenseless island in a hostile recipient sea (Figure 1.1(a)).

Tolerance

In this context, an unsolved mystery of biology for nearly 40 years was how allografts could escape rejection without the recipient being crippled with immunosuppression. The description of acquired tolerance by Billingham, Brent, and Medawar (1953, 1956) did not provide an answer. In their experimental model, immunocompetent adult spleen cells were injected in utero or perinatally into mice that had not yet evolved the necessary immunologic maturity to reject them. The engrafted cells flourished and were thought to have in effect endowed the recipient with the donor immune system (donor leukocyte chimerism) (Figure 1.1(b)).

Thereafter, the mice failed to recognize donor strain skin grafts or other tissues as alien (i.e. they had acquired tolerance). The switch in immunologic apparatus was consistent with the definition of transplantation immunology in terms of a unidirectional immune reaction (the “one-way paradigm”). Main and Prehn (1955) demonstrated the same tolerance outcome as Billingham et al. in irradiated adult mice, whose cytoablated hematolymphopoietic cells were reconstituted with bone marrow instead of spleen cells. Thousands of subsequent tolerance induction experiments in animals, and eventually clinical bone marrow transplantation, seemingly depended upon a similar natural, or iatrogenically imposed, defenseless recipient state (Figure 1.1(b)).

Graft-versus-host disease

It was recognized as early as 1957 in mouse (Billingham and Brent 1957) and chicken (Simonsen 1957) models that an immunologically active graft had a genetically controlled repertoire of immune reactivity comparable to that of the recipient, and could therefore turn the tables and reject the recipient. This was called graft-versus-host disease (GVHD), or alternatively “runt disease”. The risk if the host was immunologically defenseless was roughly propor-

tional to the extent of the major histocompatibility complex (MHC) difference between donor and recipient. Such disparities became measurable serologically in humans after identification of the human leukocyte antigens (HLAs) by Dausset (1990; Nobel Laureate 1980), Terasaki, and others whose reminiscences have been collected (Terasaki 1990). The complication of GVHD in rodent (Trentin 1957) and large animal irradiation chimera models (Mannick et al. 1959; Hume et al. 1960; Rapaport et al. 1979; Thomas 1991) forestalled for many years the clinical use of HLA mismatched bone marrow cells or other mature immunocytes, either for immunologic reconstitution with purely hematologic objectives or as a means of facilitating whole-organ graft acceptance.

Clinical bone marrow transplantation

The strategy that made possible the first successful clinical bone marrow transplantations in 1968 was an extension of the rodent experiments, with similar histocompatibility-imposed restrictions (Mathe et al. 1963; Bach 1968; Gatti et al. 1968). After recipient cytoablation with total body irradiation (TBI) or cytotoxic drugs (Figure 1.1(b)), stable chimerism could be induced in humans by the infusion of donor bone marrow, but only if there was a good HLA match. Otherwise there was an intolerable incidence of lethal GVHD. Maintenance immunosuppression could frequently be stopped in these patients, mimicking the kind of acquired immunologic tolerance originally described by Billingham et al. (1953, 1956), and by Main and Prehn (1955).


Clinical organ transplantation

Ironically, surgeons and physicians had recorded thousands of successful human whole-organ transplantations (mostly kidneys) by the time bone marrow transplantation was finally accomplished. However, the conditions were dramatically different. First, continuous immunosuppression was needed, presumably for life. Second, success did not depend on HLA matching. Third, the complication of GVHD was rare. Most immunologists were dumbfounded by these results. The inability to explain them detached workers in the whole-organ field from the scientific base enjoyed by bone marrow transplanters. Thus, further steps in the improvement of whole-organ transplantation were largely the product of trial and error. To comprehend how this occurred requires a historical perspective.

With total body irradiation

Host preconditioning played an important role in the first six successful renal

(a) One-Way Paradigm (Organ)



(c) Two-way Paradigm (Organ)






Figure 1.1. Upper panels: One-way paradigm in which transplantation is conceived as involving a unidirectional immune reaction: host-versus-graft (HVG) with whole organs (a) and graft-versus-host (GVH) with bone marrow or other lymphopoietic transplants (b). Lower panels: Two-way paradigm with which transplantation is seen as a bidirectional and mutually cancelling immune reaction that is predominantly HVG with whole-organ grafts (c), and predominantly GVH with bone marrow grafts and (d).

(b) One-Way Paradigm (Bone Marrow)



(d) Two-way Paradigm (Bone Marrow)



transplantations (defined as survival to more than one year) between 1959 and 1962, one in Boston (Merrill et al. 1960) and five in France (Hamburger et al. 1962; Kuss et al. 1962). The recipients were prepared for operation with sublethal TBI, but without donor bone marrow; their own bone marrow recovered and one of these patients (in Paris) survived for 26 years. However, these were isolated successes in a sea of failures, and pessimism set in worldwide about the prospects of moving forward.

Chemical immunosuppression

The introduction, for human renal transplantation, of 6-mercaptopurine (6-MP) and its analogue azathioprine did not at first relieve the frustration. The clinical use of these drugs followed the demonstration of their immunosuppressive effects in extensive experimental studies, first with rodent skin transplantation (Meeker et al. 1959; Schwartz and Dameshek, 1960) and then with the canine kidney transplant models (Calne 1960, 1961; Zukoski, Lee, and Hume 1960; Murray et al. 1962). The drugs had been developed originally for their antileukemic effect by Elion and Hitchings (Nobel Laureates, 1988; Elion, Bieber, and Hitchings 1955) and were first demonstrated to be immunosuppressive by Schwartz and Dameshek (1959). Although the kidney of the sixth patient treated by Murray with one of these myelotoxic drugs had the function of a non-related renal allograft for 17 months, the clinical results with chemical immunosuppression were generally poor at first (Murray et al. 1962, 1963), similar to those with TBI.

The drug cocktail breakthrough

The tidal wave of whole-organ cases began in earnest in 1962–3, when a characteristic cycle of convalescence was identified in which kidney rejection could be reversed surprisingly easily when prednisone was added to azathioprine (double-drug therapy) (Starzl, Marchioro, and Waddell 1963). More importantly, the need later on for maintenance immunosuppression often declined as if the immune barrier had been lowered (Figure 1.2), and in occasional cases therapy could be stopped. Since then, the same sequence has been seen with all other organs transplanted and with all of the two-drug and more complex multiple agent immunosuppressive regimens. Drugs introduced later were more potent and reliable in chaperoning the desired chain of events: antilymphocyte globulin (ALG) (Starzl et al. 1967), cyclosporine (Calne et al. 1979), and FK506 (Starzl et al. 1989). Notwithstanding their diversity, all seemed in a fundamentally similar way to have allowed something to change in the host, the graft or both. But what?

Deficiencies of the one-way paradigm

Although the one-way paradigm did not provide the answer, this false




Figure 1.2. Pattern of postoperative events with whole-organ allograft acceptance, in the framework of the one-way paradigm. HVG, host-versus-graft.

conceptualization of graft acceptance as a product of a unidirectional reaction was reinforced with the introduction in 1963 of the one-way mixed lymphocyte reaction (Bach and Hirschhorn 1964; Bain, Vas, and Lowenstein 1964). Although these and other *in vitro* techniques (the so-called minitransplant models) generated increasingly sophisticated cellular and ultimately molecular studies of one-way immunologic reactions, the resulting plethora of new information resembled an exponentially expanding telephone directory. Most seriously, the flawed context lured successive generations of investigators into the trap of believing that tolerance induction for whole-organ recipients (the “holy grail”) lay in variations on the HLA-limiting strategy used for bone marrow transplantation. The strategy always included host preconditioning in preparation for a variety of donor leukocyte preparations.

Cell-mediated immunity

The inability of clinicians to explain what was going on with their patients did not dissuade them from developing their own voluminous literature which, was largely phenomenologic. An increasing number of transplant surgeons and physicians began to regard basic immunology as an interesting hobby, but one that was irrelevant to their practice. Meanwhile, most virologists and the majority of basic immunologists trying to understand rejection had shifted their efforts by the early 1970s from whole-animal studies to T




Figure 1.3. A schematic representation of the antiallograft immune response showing the cell surface proteins that participate in antigen recognition and signal transduction, the contribution of cytokines and the sites of action of the diverse agents that prolong graft survival. Antigen (allopeptide) recognition via the T cell receptor (TCR) and the role of accessory molecules can be blocked by monoclonal antibodies (MA), as can cytokine receptor expression. Deoxyspergualin (D) is believed to inhibit the function of antigen-presenting cells (APC). FK506 (F, now tacrolimus) and cyclosporine (C) inhibit cytokine gene expression within T helper (TH) cells, whereas rapamycin (R) blocks the responses of T cells to interleukin (IL)-2. By inhibiting DNA synthesis, the antimetabolite drugs (A) act later than F, C or R to block lymphocyte proliferation. CTLA4-Ig (CT) is a new agent that blocks transmission of second signal (the B7-CD28) pathway essential for T cell activation. F/C, FK506/CsA (cyclosporin A). (I) and (II) indicate major histocompatibility complex (MHC) antigens classes I and II, respectively.

lymphocyte-oriented cell culture (in vitro) systems. These labors were rewarded by a Nobel Prize (to Baruj Benacerraf, 1980) and the Lasker Prize in Basic Science of 1995, which was shared by four Americans and one Swiss (Doherty 1995; Unanue 1995; Zinkernagel 1995). The conceptual model that

emerged provided an explanation of cell-mediated immunity (Figure 1.3). In the context of the one-way paradigm, the details of the putative allogeneic reaction (rejection) included its dependence on antigen-presenting cells, the necessity for a co-stimulatory molecule(s) (the two-signal concept of self/non self discrimination), an important role of accessory molecules, and cytokine control of clonal expansion of T helper lymphocytes as well as of the cytotoxic T cells that are the agents of allograft destruction. The bewildering mass of details to which thousands of investigators had contributed over three decades (Janeway and Travers 1994) had long since overwhelmed most clinicians interested in applying the new information.

Mechanisms of drug action

However, the foregoing information allowed precise documentation of the surprising diversity of drugs with which long-term or permanent graft survival could be induced, no matter what the level of intervention in the immune reaction (Thomson and Starzl 1994). This is summarized in Figure 1.3. Deoxyspergualin was said to alter the function of antigen-presenting cells, of which dendritic cells have been conceded to be the most important. The anti metabolite drugs (including azathioprine) prevented clonal expansion of lymphocytes by inhibition of DNA synthesis. Cyclosporine and tacrolimus (FK506) disrupt signals from T cell receptor sites to the nucleus. Monoclonal antibodies (MAs) interrupt the immune reaction at the various specific targets (Figure 1.3), and rapamycin interdicts the effector events even after the secretion of the cytokine interleukin 2 (formerly called the “T cell growth factor”). The new immunosuppressive fusion protein CTLA4-Ig blocks the transmission of a “second signal” (the B7-CD28 pathway). All appear to be permissive of a natural event that became specific only by virtue of the presence of donor antigens.

The immunologic barrier: the two-way paradigm

Whole-organ transplantation

Insight into what had happened to the pioneer organ recipients was obtained in retrospect by studies, at the University of Pittsburgh nearly 30 years later, of a group of kidney and liver recipients from the earliest clinical trials at the University of Colorado, who still had good function of their original grafts. Donor leukocytes of bone marrow origin that are part of the structure of all complex grafts (“passenger leukocytes” (Snell 1957; Steinmuller 1967)) were found in 1992 to have migrated from the organs and survived ubiquitously in the patients for up to three decades (Starzl et al. 1992, 1993). Thus, organ allograft acceptance was associated with the cryptic persistence of a small

fragment of extramedullary donor marrow, including stem cells (depicted as a bone silhouette in Figure 1.1(c)). These cells had been assimilated into the overwhelmingly larger immunologic network of the host. The leukocyte movement was in both directions, with small numbers of residual donor leukocytes (microchimerism) in both the graft and host.

The discovery was instinctively understood by most patients to whom it was explained, and it had a surprisingly great emotional impact. The point was not lost that the physical intimacy of the donor to the recipient was greater than anyone had ever imagined. It was closer and more lasting than that of a gestational fetus with its mother. The woman applying lipstick in the morning was touching that unknown cadaveric male donor of 30 years ago whose live cells were everywhere in her own tissue. She was not the recipient of an organ only. The realization was usually moving, and it was invariably sobering.

Scientifically, a revision of transplantation immunology was mandated in which the immunologic confrontation following whole-organ transplantation could be seen as a bidirectional and mutually cancelling (graft-versus-host (GVH) as well as host-versus-graft (HVG)) interaction (Figure 1.4), provided the two participants in the David (donor)/Goliath (recipient) mismatch could survive the initial confrontation. Clinically, but not in several animal models, this outcome requires an umbrella of immunosuppression that protects both cell populations equally (Figure 1.1(c)).

Understanding the amplification device by which the small number of donor cells can so profoundly affect the immunologic vision of, and eventually be assimilated by, the vast recipient army against which it is arrayed is of intense scientific interest. The chimeric leukocytes are multilineage (Starzl et al. 1992, 1993; Demetris et al. 1993; Qian et al. 1994). However, the antigen-presenting dendritic cells (DCs) of Steinman and Cohn (1973; Steinman 1991) are thought to be the key to the reciprocal tolerogenic process because they can modify in both cell populations the expression of cell interaction, MHC, and adhesion molecules. All of these interactions determine how antigen signals are responded to by T cells (Steinman 1991). Evidence confirming the original observations, allowing a more complete understanding of the tolerogenic mechanisms, has been summarized recently (Starzl and Zinkernagel 1998).

Historical enigmas

With the two-way paradigm, the reason for virtually every previously unexplained experimental or clinical observation after whole-organ transplantation became either transparent, or at least susceptible to experimental inquiry (Starzl et al. 1992, 1993). It could be understood why organ grafts are inherently tolerogenic and therefore “accepted” by the recipient. With the




Figure 1.4. The pattern of convalescence after either organ or bone marrow transplantation in the framework of the two-way paradigm. HVG, host-versus-graft; GHV, graft-versus-host.

two-way mutual cancellation implicit in this concept, the loss or blunting of an HLA-matching effect was comprehensible. With each further level of histoincompatibility, the reciprocal effect apparently escalates both ways under the umbrella of an effective immunosuppressant (Figure 1.5). The consequent dwindling of the matching effect as donor-specific and recipient-specific nonreactivity evolves accounts for “blindfolding” of the expected HLA influence.

In addition to explaining why the HLA-matching effect is mitigated, the mutual functional cancellation of the two cell populations explains why GVHD does not develop after liver, intestinal, multivisceral, and heart–lung transplantation, despite the heavy lymphoid content of those organs. The safety of these procedures depended on leaving the recipient immunologic system intact until the time of transplantation.

Augmentation of spontaneous chimerism

Because the acquisition of immunologic tolerance in the originally Billingham–Brent–Medawar and derivative models depended on donor leukocyte (splenocyte or bone marrow) infusion (Billingham et al. 1953, 1956; Main and Prehn 1955), sporadic attempts had been made to improve organ allograft outcome by infusing adjuvant donor bone marrow (Monaco, Clark, and Brown 1976; Barber et al. 1991) or blood (Salvatierra et al. 1980; Anderson, Sicard, and Etheredge 1982; Sollinger et al. 1984). These were




Figure 1.5. Explanation for the loss of an HLA-matching effect with whole-organ transplantation. Rx: immunosuppression.

hampered by the assumption that the infused cells would be destroyed unless there was recipient preconditioning with irradiation or myelotoxic drugs. In turn, the prospect of recipient cytoablation engendered anxiety about causing GVHD. Most importantly, the appropriate timing of the cell infusions was controversial. Consequently, the strategy of donor leukocyte augmentation never gained a clinical foothold.

The discoveries of leukocyte chimerism in 1992 (Starzl et al. 1992, 1993) exposed a perioperative window of opportunity during which unaltered

Two-Way Paradigm (Heart)




Figure 1.6. Iatrogenic augmentation of the graft-versus-host (GVH) component of the two-way paradigm by infusing 3×10^8 to 6×10^8 /kg unaltered donor bone marrow cells at the same time as heart or other whole-organ transplantation. When the recipient is not cytoablated, there is essentially no risk of GVHD.

HLA-incompatible bone marrow or donor-specific blood transfusion was predicted to be safe without recipient preparation or any other deviation from the generic noncytoablative practices of immunosuppression for whole-organ transplantation that had evolved over the years from the original azathioprine–prednisone formula (Starzl et al. 1963). The validity of this expectation was verified recently in nonpreconditioned recipients of cadaveric kidneys, livers, hearts, and lungs who were given adjuvant bone marrow cells at 3×10^8 to 5×10^8 /kg at the same time as organ transplantation under standard tacrolimus–prednisone treatment (Figure 1.6) (Fontes et al. 1994).

Chimerism estimated to be > 1000 times that occurring in conventional whole-organ recipients was reliably and safely produced and sustained. The persistent blood chimerism (usually $> 1\%$), trend toward donor specific nonreactivity, and high rate of patient and graft survival, have marked these bone marrow augmented recipients as an advantaged cohort. They are the first patients to undergo HLA-mismatched cadaveric organ transplantation with the hope of eventually becoming drug free. The process of tolerance induction and drug weaning is expected to take 5 to 10 years, but in some the drug-free state may never be attainable.

The drug-free state

The concept that organ transplantation is equivalent to a small bone marrow transplantation (and that this explains allograft acceptance) has been confirmed and greatly extended in animal models, principally by Qian et al. (1994) and by Demetris et al. (1993) and Murase et al. (1995). The cardinal principle is that the long and continuing survival of an organ allograft means, by definition, that donor leukocyte chimerism is present. Failure to demonstrate chimerism in such recipients connotes an inadequate search (Murase et al. 1995).

However, donor leukocyte chimerism is merely a prerequisite for graft acceptance (Starzl et al. 1992). Is the demonstration of chimerism an indication to stop immunosuppression? Emphatically no! However, knowledge of the chimerism mechanism makes it clear why drugs can in fact be stopped permanently after organ transplantation in some cases. In late 1995, 12 (28%) of the 43 longest surviving liver recipients in the world (14 to 26 years) have been off drugs for 1 to almost 19 years. Complementing these observations, Ramos et al. (1995) have reported a prospective weaning trial for liver recipients, limited for the most part to patients who were 5 to 10 years post-transplantation. Freedom from rejection for at least 5 years was a prerequisite for admission to the trial, which has expanded to 80 patients. Forty-four (55%) of these liver recipients have come off drugs completely or have moved uninterruptedly in that direction; in 22 whose weaning is complete, the drug-free time averages $2\frac{1}{2}$ years. Weaning is being carried out more slowly now than at the beginning of the trial because of a 30% incidence of rejection. It was evident that the vast majority of the 80 liver recipients had been at a level of immunosuppression higher than they needed. It is more dangerous to attempt weaning after kidney transplantation, and we rarely recommend this. However, five of our longest-surviving living related kidney recipients have been off all immunosuppression for 2 to 30 years. A recent report has documented these results (Mazariegos et al. 1997).

Rejection after drug discontinuance

The benefits of weaning for organ recipients are obvious. However, it is equally important to recognize that there was a 30% overall risk of rejection in the prospective liver trial. Successful weaning was achieved consistently only in the patients being weaned from an azathioprine–prednisone regimen or from monotherapy with tacrolimus (Ramos et al. 1995). When weaning failed, biopsy-proved rejection was diagnosed 1 to 29 months after drug withdrawal was started and usually was classed histopathologically as minimal to mild. Restoration of the previous baseline immunosuppression was the only adjustment required in most cases, but four patients with moderate or severe rejection required rescue treatment with tacrolimus; this included




Figure 1.7. The growth, as separate disciplines, of bone marrow (right) and whole-organ transplantation (left) from the seed planted by Peter Medawar during World War II. It was recognized in 1992 that these seemingly disparate disciplines were mirror images caused by different treatment strategies as explained in the text. GVHD, graft-versus-host disease.

one who became jaundiced, with a peak bilirubin of 12 mg%. Although no patients or grafts were lost in our trial, Sandborn et al. (1994) encountered rejection in 6 of 12 patients at the Mayo Clinic whose rapid weaning from cyclosporine-based triple drug therapy was attempted after only three post-transplant years; two of the six died. It would be foolhardy to ignore such a warning.

Bone marrow transplantation

When it was discovered that successful whole-organ transplantation was associated with spontaneous chimerism, it was realized that the seemingly vast gap between the bone marrow and whole-organ transplantation fields reflected entrenched differences in treatment strategy (Figure 1.7). The mutually censoring immunologic limbs were being left intact with organ transplantation, whereas the recipient limb was deliberately removed (cytoablation) in preparation for bone marrow grafting procedures. Although it was long assumed that the entire recipient immune system had been eliminated with successful bone marrow transplantation (Figure 1.1(b)), a trace population of recipient leukocytes has been detected with sensitive techniques in the blood of almost all such patients (Przepiorka et al. 1991; Wessman et al. 1993).

These bone marrow recipients were in fact mirror images of those

successfully bearing whole-organ allografts, the difference being that their own residual leukocytes rather than those of the donor constituted the trace population. Under both circumstances, other findings such as the appearance of veto and suppressor cells, enhancing antibodies, and changes in cytokine profile could be construed as by-products, of and accessory to, the seminal event of the mutual cell engagement (Figure 1.1(c) and (d)).

Conclusions

In this chapter, a generic explanation has been provided for what has been one of the most remarkable and in some respects conceptually enigmatic developments in the history of medicine. Successful engraftment of the kidney (Merrill et al. 1960), pancreas (Lillehei et al. 1970), liver (Starzl et al. 1968), heart (Barnard 1968), lung (Derom et al. 1971), and multiple abdominal viscera (Starzl et al. 1989) intestine (Goulet et al. 1992) were empirical achievements, accomplished largely by dogged trial and error. Each organ-defined specialty has had its historians who track their story back to one of the foregoing milestones where the trail goes cold. The reason is that such accounts have been preoccupied with a succession of events rather than the biologic principles that are applicable to all organ allografts. Escape from this intellectual cul de sac became possible with the discovery in 1992 that donor leukocyte chimerism occurs spontaneously after organ transplantation, and the development of evidence that this is the basis of graft acceptance.

Beacons of understanding shine forward as well as back. Comprehension of the history of transplantation in terms of the two-way paradigm (Starzl and Demetris 1995) provides the conceptual means to devise better treatment strategies, including the achievement of drug-free tolerance. If the goal of xenotransplantation is attained (and it may be soon), the same ubiquitous mix of two genetically different leukocyte populations as that following allotransplantation will be a necessary condition. Although the diffuse distribution of donor leukocytes in organ recipients is not thought to affect central nervous system changes, the emotional and psychiatric implications of creating animal/human genetic composites via xenotransplantation cannot be taken lightly.

Acknowledgments

From the Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA. This work was supported in part by research grants from the Veterans Administration and Project Grant no. DK-29961 from the National Institutes of Health, Bethesda, MD.

References

- Anderson, C. B., Sicard, G. A., and Etheredge, E. E. (1982). Pretreatment of renal allograft recipients with azathioprine and donor-specific blood products. *Surgery*, **92**, 315–41.
- Bach, F. H. (1968). Bone-marrow transplantation in a patient with the Wiskott–Aldrich syndrome. *Lancet*, **2**, 1364–6.
- Bach, F. and Hirschhorn, K. (1964). Lymphocyte interaction: a potential histocompatibility test in vitro. *Science*, **143**, 813–14.
- Bain, B., Vas, M. R., and Lowenstein, L. (1964). The development of large immature mononuclear cells in mixed leukocyte cultures. *Blood*, **23**, 108–16.
- Barber, W. H., Mankin, J. A., Laskow, D. A. et al. (1991). Long-term results of a controlled prospective study with transfusion of donor specific bone marrow in 57 cadaveric renal allograft recipients. *Transplantation*, **51**, 70–5.
- Barnard, C. N. (1968). What we have learned about heart transplants? *J Thorac Cardiovasc Surg*, **56**, 457–68.
- Billingham, R. and Brent, L. (1957). A simple method for inducing tolerance of skin homografts in mice. *Transplant Bull*, **4**, 67–71.
- Billingham, R. E., Brent, L., and Medawar, P. B. (1953). “Actively acquired tolerance” of foreign cells. *Nature*, **172**, 603–6.
- Billingham, R., Brent, L., and Medawar, P. (1956). Quantitative studies on tissue transplantation immunity. III. Actively acquired tolerance. *Phil Trans R Soc Lond B Biol Sci*, **239**, 357–412.
- Brown, J. B. (1937). Homografting of skin: with report of success in identical twins. *Surgery*, **1**, 558–63.
- Burnet, F. M. (1961). The new approach to immunology. *N Engl J Med*, **264**, 24–34.
- Calne, R. Y. (1960). The rejection of renal homografts: inhibition in dogs by 6-mercaptopurine. *Lancet*, **1**, 417–18.
- Calne, R. Y. (1961). Inhibition of the rejection of renal homografts in dogs with purine analogues. *Transplant Bull*, **28**, 445.
- Calne, R. Y., Rolles, K., White, D. J. G. et al. (1979). Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. *Lancet*, **2**, 1033–6.
- Dausset, J. (1990). The HLA adventure. In *History of HLA: Ten Recollections*, ed. P. I. Terasaki, pp. 1–20. UCLA Tissue Typing Laboratory: Los Angeles.
- Demetris, A. J., Murase, N., Fujisaki, S., Fung, J. J., Rao, A. S., and Starzl, T. E. (1993). Hematolymphoid cell trafficking, microchimerism, and GVHD reactions after liver, bone marrow, and heart transplantation. *Transplant Proc*, **25**, 3337–44.
- Derom, F., Barbier, F., Ringoir, S. et al. (1971). Ten-month survival after lung homotransplantation in man. *J Thorac Cardiovasc Surg*, **61**, 835–46.
- Doherty, P. C. (1995). The keys to cell-mediated immunity. *JAMA*, **274**, 1067–8.
- Elion, G. B., Bieber, S., and Hitchings, G. H. (1955). The fate of 6-mercaptopurine in mice. *Ann NY Acad Sci*, **60**, 297–303.
- Fontes, P., Rao, A., Demetris, A. J. et al. (1994). Augmentation with bone marrow of donor leukocyte migration for kidney, heart, and pancreas islet transplantation. *Lancet*, **344**, 151–5.
- Gatti, R. A., Meuwissen, H. J., Allen, H. D., Hong, R., and Good, R. A. (1968).

- Immunological reconstitution of sex-linked lymphopenic immunological deficiency. *Lancet*, **2**, 1366–9.
- Goulet, O., Revillon, Y., Brousse, N. et al. (1992). Successful small bowel transplantation in an infant. *Transplantation*, **53**, 940–3.
- Hamburger, J., Vaysse, J., Crosnier, J., Auvert, J., LaLanne, A. M., and Hopper, J., Jr. (1962). Renal homotransplantation in man after radiation of the recipient. *Am J Med*, **32**, 854–71.
- Hume, D. M., Jackson, B. T., Zukoski, C. F. et al. (1960) The homotransplantation of kidneys and of fetal liver and spleen after total body irradiation. *Annals of Surgery*, **152**, 354–78.
- Janeway, C. A., Jr. and Travers, P. (1994). *Immunobiology*. Garland Publishing Inc.: New York.
- Kuss, R., Legrain, M., Mathe, G., Nedey, R., and Camey, M. (1962). Homologous human kidney transplantation. Experience with six patients. *Postgrad Med J*, **38**, 528–31.
- Lillehei, R. C., Simmons, R. L., Najarian, J. S., Weil, R., Uchida, H., Ruiz, J. D., Kjellstrand, C. M., and Goetz, F. C. (1970). Pancreaticoduodenal allotransplantation: experimental and clinical observations. *Ann Surg*, **172**, 405–36.
- Main, J. M. and Prehn, R. T. (1955). Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. *J Natl Cancer Inst*, **15**, 1023–9.
- Mannick, J. A., Lochte, H. L. Ashley, C. A., Thomas, E. D., and Ferrebee, J. W. (1959). A functioning kidney homotransplant in the dog. *Surgery*, **46**, 821–8.
- Mathe, G., Amiel, J. L., Schwarzenberg, L., Cattani, A., and Schneider, M. (1963). Haematopoietic chimera in man after allogenic (homologous) bone marrow transplantation. *Br Med J*, 1633–5.
- Mazariegos, G. V., Reyes, J., Marino, I. et al. (1997). Long-term follow-up of weaning of immunosuppression in liver transplant recipients. *Transplantation*, **63**, 243–9.
- Medawar, P. B. (1944). The behavior and fate of skin autografts and skin homografts in rabbits. *J Anat*, **78**, 176–99.
- Meeker, W., Condie, R., Weiner, D., Varco, R. L., and Good, R.A. (1959). Prolongation of skin homograft survival in rabbits by 6-mercaptopurine. *Proc Soc Exp Biol Med*, **102**, 459–61.
- Merrill, J. P., Murray, J. E., Harrison, J. H., Friedman, E. A., Dealy, J. B., Jr., and Dammin, G. J. (1960). Successful homotransplantation of the kidney between non-identical twins. *New Engl J Med*, **262**, 1251–60.
- Merrill, J. P., Murray, J. E., Harrison, J. H., and Guild, W. R. (1956). Successful homotransplantation of the human kidney between identical twins. *JAMA*, **160**, 277–82.
- Monaco, A. P., Clark, A. W., and Brown, R. W. (1976). Active enhancement of a human cadaver renal allograft with ALS and donor bone marrow: case report of an initial attempt. *Surgery*, **79**, 384–92.
- Murase, N., Starzl, T. E., Tanabe, M. et al. (1995). Variable chimerism, graft versus host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to Brown-Norway rats. *Transplantation*, **60**, 158–71.
- Murray, J. E., Merrill, J. P., Dammin, G. J., Dealy, J. B., Jr., Alexandre, G.W., and Harrison, J. H. (1962). Kidney transplantation in modified recipients. *Ann Surg*,

- 156, 337–55.
- Murray, J. E., Merrill, J. P., Harrison, J. H., Wilson, R. E., and Dammin, G. J. (1963). Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. *New Engl J Med*, **268**, 1315–23.
- Padgett, E. D. (1932). Is iso-skin grafting practicable? *South Med J*, **25**, 895–900.
- Przepioraka, D., Thomas, E. D., Durham, D. M., and Fisher, L. (1991). Use of a probe to repeat sequence of the Y chromosome for detection of host cells in peripheral blood of bone marrow transplant recipients. *Hematopathology*, **95**, 201–6.
- Qian, S., Demetris, A. J., Murase, N., Rao, A. S., Fung, J. J., and Starzl, T. E. (1994). Murine liver allograft transplantation: tolerance and donor cell chimerism. *Hepatology*, **19**, 916–24.
- Ramos, H. C., Reyes, J., Abu-Elmagd, K. et al. (1995). Weaning of immunosuppression in long term liver transplant recipients. *Transplantation*, **59**, 212–17.
- Rapaport, F. T., Bachvaroff, R. J., Mollen, N., Hirasawa, H., Asano, T., and Ferrebee, J. W. (1979). Induction of unresponsiveness to major transplantable organs in adult mammals. *Ann Surg*, **190**, 461–73.
- Salvatierra, O., Jr., Vincenti, F., Amend, W. J. et al. (1980). Deliberate donor-specific blood transfusions prior to living related renal transplantation: a new approach. *Ann Surg*, **192**, 543–52.
- Sandborn, W. J., Hay, J. E., Porayko, M. K. et al. (1994). Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. *Hepatology*, **19**, 925–32.
- Schwartz, R. and Dameshek, W. (1959). Drug-induced immunological tolerance. *Nature*, **183**, 1682–3.
- Schwartz, R. and Dameshek, W. (1960). The effects of 6-mercaptopurine on homograft reactions. *J Clin Invest*, **39**, 952–958.
- Simonsen, M. (1957). The impact on the developing embryo and newborn animal of adult homologous cells. *Acta Path Microbiol Scand*, **40**, 480–500.
- Snell, G. D. (1957). The homograft reaction. *Annu Rev Microbiol*, **11**, 439–58.
- Sollinger, H. W., Burlingham, W. J., Sparks, E. M., Glass, N. R., and Belzer, F. O. (1984). Donor-specific transfusions in unrelated and related HLA-mismatched donor-recipient combinations. *Transplantation*, **38**, 612–15.
- Starzl, T. E. (1992). *The Puzzle People*. University of Pittsburgh Press: Pittsburgh.
- Starzl T. E. and Demetris, A. J. (1995). Transplantation milestones: viewed with one- and two-way paradigms of tolerance. *JAMA*, **273**, 876–9.
- Starzl, T. E., Demetris, A. J., Murase, N., Ildstad, S., Ricordi, C., and Trucco, M. (1992). Cell migration, chimerism, and graft acceptance. *Lancet*, **339**, 1579–82.
- Starzl, T. E., Demetris, A. J., Trucco, M. et al. (1993). Cell migration and chimerism after whole organ transplantation: the basis of graft acceptance. *Hepatology*, **17**, 1127–52.
- Starzl, T. E., Groth, C. G., Bretschneider, L. et al. (1968). Orthotopic homotransplantation of the human liver. *Ann Surg*, **168**, 392–415.
- Starzl, T. E., Marchioro, T. L., Porter, K. A., Iwasaki, Y., and Cerilli, G. J. (1967). The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. *Surg Gynecol Obstet*, **124**, 301–18.
- Starzl, T. E., Marchioro, T. L., and Waddell, W. R. (1963). The reversal of rejection in

- human renal homografts with subsequent development of homograft tolerance. *Surg Gynecol Obstet*, **117**, 385–95.
- Starzl, T. E., Rowe, M., Todo, S. et al. (1989). Transplantation of multiple abdominal viscera. *JAMA*, **261**, 1449–57.
- Starzl, T. E., Todo, S., Fung, J., Demetris, A. J., Venkataramanan, R., and Jain, A. (1989). FK 506 for human liver, kidney and pancreas transplantation. *Lancet*, **2**, 1000–4.
- Starzl, T. E. and Zinkernagel, R. (1998). Antigen localization and migration in immunity and tolerance. *N Engl J Med*, **339**, 1905–13.
- Steinman, R. M. (1991). The dendritic cell system and its role in immunogenicity. *Annu Rev Immunol*, **9**, 271–96.
- Steinman, R. M. and Cohn, Z. A. (1973). Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. *J Exp Med*, **137**, 1142–62.
- Steinmuller, D. (1967). Immunization with skin isografts taken from tolerant mice. *Science*, **158**, 127–9.
- Terasaki, P. I. (ed.) (1990). *History of HLA: Ten Recollections*. UCLA Tissue Typing Laboratory: Los Angeles.
- Thomas, E. D. (1991). Allogeneic marrow grafting – a story of man and dog. In *History of Transplantation: Thirty-Five Recollections*, ed. P.I. Terasaki, pp. 379–394, UCLA Press: Los Angeles.
- Thomson, A. W. and Starzl, T. E. (eds.) (1994). *Immunosuppressive Drugs: Developments in Anti-Rejection Therapy*. Edward Arnold: .
- Trentin, J. J. (1957). Induced tolerance and “homologous disease” in X-irradiated mice protected with homologous bone marrow. *Proc Soc Exp Biol Med*, **96**, 139–44.
- Unanue, E. R. (1995). The concept of antigen processing and presentation. *JAMA*, **274**, 1071–3.
- Wessman, M., Popp, S., Ruutu, T. Volin, L., Cremer, T., and Knuutila, S. (1993). Detection of residual host cells after bone marrow transplantation using non-isotopic in situ hybridization and karyotype analysis. *Bone Marrow Transplant*, **11**, 279–84.
- Zinkernagel, R. M. (1995). The MHC-restricted T-cell recognition. *JAMA*, **274**, 1069–71.
- Zukoski, C. F., Lee, H. M., and Hume, D. M. (1960). The prolongation of functional survival of canine renal homografts by 6-mercaptopurine. *Surg Forum*, **11**, 470–2.